The Bioavailability/Bioequivalence Focus Group (BA/BE FG) is part of FIP’s Special Interest Group on Regulatory Science. It aims to offer up-to-date information on BA/BE of oral drugs and to discuss the international harmonisation in regulating and controlling the quality of oral drug products.
The goals of the BA/BE FG are to:
- Understand up-to-date science and technology relating to oral bioavailability of drugs for contributing to the development of effective and safe oral drug products.
- Understand the current status of regulatory issues for oral drug products and proposing international standards.
The group organises international symposia on the bioavailability/bioequivalence of oral drug products (“Babe”). The first BA/BE symposium was held in Kobe, Japan, in 2011, the second was in Seoul, Republic of Korea, in 2014, and the third BA/BE symposium was held in Lisbon, Portugal, in October 2018.
The group is chaired by Prof. Shinji Yamashita. For further information,